Gerd

In value-based care programs, inflammatory bowel diseases like Crohn’s disease and ulcerative colitis may require more intense management compared with other chronic gastrointestinal conditions due to much higher cost volatility, according to data from DDW.

There was no evidence of increased risk for various cancers among patients who used ranitidine compared with those who used famotidine; however, ranitidine users compared with the general population were more likely to have a cancer diagnosis and other risk factors for cancer, according to data from Digestive Disease Week.

The FDA has requested that manufacturers withdraw all prescription and over-the-counter ranitidine drugs and advised patients to discontinue taking over-the-counter versions of the drug, according to an agency release.

Survey results revealed most internists perceived proton pump inhibitors were linked with numerous adverse events and recommended their discontinuation even in patients who are high risk for upper gastrointestinal bleeding.

The portrayal of proton pump inhibitors in the news lately has been rather bleak. Concerns for increased risks for dementia, malignancies and other serious adverse events have populated our television sets and mainstream media over the last several years.

The FDA has given breakthrough device designation to the EsoGuard Esophageal DNA Test designed to help identity patients at higher risk for dysplasia due to chronic GERD, according to a press release from Lucid Diagnostics.

Healio Gastroenterology and Liver Disease presents the following reports on the most recent research on the esophagus and GERD.

SAN ANTONIO — A comprehensive gastroenterologist-supervised weight management program that includes nutrition education and behavioral support groups may lead to significant weight loss in obese patients with non-alcoholic fatty liver and GERD, according to findings presented at the American College of Gastroenterology Annual Meeting.

A study that found people who reported recent use of marijuana were less like to experience constipation was the week’s top story in gastroenterology.

A week after halting the distribution of Zantac, Sandoz, the drug’s manufacturer, voluntarily recalled several formulations of the heartburn medication after noting confirmed contamination with N-Nitrosodimethylamine (NDMA), a possible human carcinogen, above established FDA levels.